EML4 and lung cancer: In contrast to transgenetic mouse models driven by other oncogenes that usually develop tumors around 3 to 6 months after birth, the lung-specific EML4-ALK transgenetic mice have develop multiple lung cancer nodules in both lungs without latency after birth, and inhibition of ALK leads to dramatic tumor regression in vivo.